Neue Studien: Psoriasis im JDDGhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/page/2/?d=1Neue Studien: Psoriasis im JDDGdeS1‐Leitlinie für bildgebende Diagnostik von Hauterkrankungenhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s1%E2%80%90leitlinie-f%C3%BCr-bildgebende-diagnostik-von-hauterkrankungen-r383/No abstract supplied.

Weiterlesen

]]>383Thu, 18 Dec 2025 08:21:11 +0000S1 guideline for imaging diagnostics for skin diseases.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s1-guideline-for-imaging-diagnostics-for-skin-diseases-r382/Weiterlesen

]]>382Thu, 18 Dec 2025 08:21:11 +0000Erfolgreiche Behandlung einer palmoplantaren Pustulose mit topischem Ruxolitinibhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/erfolgreiche-behandlung-einer-palmoplantaren-pustulose-mit-topischem-ruxolitinib-r381/No abstract supplied.

Weiterlesen

]]>381Thu, 18 Dec 2025 08:21:11 +0000The role of phototherapy in reducing the risk of psoriatic arthritis among psoriasis patients in the era of biologics - A single center exploratory retrospective cohort study.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/the-role-of-phototherapy-in-reducing-the-risk-of-psoriatic-arthritis-among-psoriasis-patients-in-the-era-of-biologics-a-single-center-exploratory-retrospective-cohort-study-r380/Background and objectivesBiologic therapies for psoriasis have shown promise in reducing the risk of Psoriatic Arthritis (PsA) by targeting inflammatory pathways. Emerging evidence suggests that phototherapy may also exert systemic anti-inflammatory effects. This study examines the impact of phototherapy on the progression to PsA.

Patients and methods

This exploratory, hypothesis generating retrospective cohort study comprised 667 psoriatic patients, subclassified based on therapeutic interventions administered during longitudinal follow-up: phototherapy alone; phototherapy combined with systemic therapy [either conventional agents (e.g., methotrexate, acitretin, cyclosporine) or biologics (e.g., TNF inhibitors, anti-IL-12/23, anti-IL-17A, anti-IL-23A); topical therapy alone; and systemic monotherapy. PsA diagnoses were established in accordance with the Classification Criteria for Psoriatic Arthritis.

Results

Patients receiving standalone phototherapy exhibited a reduced PsA incidence compared to those on topical agents (4.09 vs 5.30 events per 100 person-years; HR = 0.73; 95 % CI: 0.53-0.99; p = 0.047). Combining phototherapy with systemic therapy further reduced PsA risk compared to systemic monotherapy (2.26 vs 3.74 events per 100 person-years; HR = 0.56; 95 % CI: 0.38-0.82; p = 0.003). The lowest incidence was observed in patients treated with both phototherapy and biologics, outperforming biologics alone (HR = 0.43; 95 % CI: 0.19-0.93; p = 0.03).

Conclusions

Phototherapy, especially in combination with systemic treatments, demonstrates synergistic potential in mitigating PsA risk.

Weiterlesen

]]>380Thu, 18 Dec 2025 08:21:11 +0000Inconsistent standard of care for tuberculosis screening and preventive therapy before initiating systemic psoriasis treatment.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/inconsistent-standard-of-care-for-tuberculosis-screening-and-preventive-therapy-before-initiating-systemic-psoriasis-treatment-r369/Background and objectivesPreventive tuberculosis (TB) therapy before initiating MTX or IL-17/IL-23/IL-12/23p40 inhibitors for latent tuberculosis infection (LTBI) is supported by indirect evidence of TB reactivations with TNF inhibitors. However, direct evidence for MTX or IL-17/IL-23/IL-12/23p40 inhibitors is limited. To better evaluate the risk of TB reactivation, data on LTBI patients exposed to these medications without preventive TB therapy are necessary. This study was conducted as part of the update of the European and German psoriasis guidelines aimed to assess current LTBI screening and preventive treatment practices.

Patients and methods

An online survey was distributed via German, European and international dermatological societies, yielding 326 complete responses.

Results

LTBI screening was performed by 45% of respondents before MTX initiation and 95% before IL-17/IL-23/IL-12/23p40 inhibitors. Preventive TB therapy was initiated "always" or "almost always" in 38% of MTX cases and "never" or "almost never" in 31%. For IL-17/IL-23/IL-12/23p40 inhibitors, preventive TB therapy was used in 66% of cases "always" or "almost always," 16% case-by-case and 9% "never" or "almost never."

Conclusions

LTBI screening and preventive TB therapy for MTX lack standardization. While screening is common for IL-17/IL-23/IL-12/23p40 inhibitors, a significant proportion of LTBI patients receive these treatments without preventive TB therapy.

Weiterlesen

]]>369Sun, 30 Nov 2025 16:48:12 +0000Impact of adalimumab treatment on impairment of non-professional activities in psoriasis patients.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/impact-of-adalimumab-treatment-on-impairment-of-non-professional-activities-in-psoriasis-patients-r368/Background and objectivesPsoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non-professional activities. This study investigates the effects of long-term treatment with adalimumab regarding work ability, non-professional activities, and health-related quality of life in a large real-word population in Germany.

Patients and methods

Single-arm, multicenter non-interventional study to document routine care data for up to 5 years in adult patients with psoriasis after initiation of adalimumab.

Results

Baseline data was collected for 4,793 (62.1 % male) patients with a mean (± SD) age of 47.5 ± 13.11 years. The number of days with restrictions in non-professional activities was much higher than in professional activities. Under adalimumab, the psoriasis-related number of days unfit for work and number of days with restrictions in non-professional activities significantly decreased. Correlation analyses showed that psoriatic arthritis, disease severity (PASI > 10), and impairment of quality of life (DLQI > 10) are associated with restrictions in non-professional activities. Health-related quality of life improved over the observed time but remained reduced in patients with restrictions in non-professional activities.

Conclusions

Long-term treatment with adalimumab had a favorable impact on clinical outcomes, employment-related aspects, practice of non-professional activities, and health-related quality of life in psoriasis patients.

Weiterlesen

]]>368Sun, 30 Nov 2025 16:48:12 +0000Use of non-invasive optical imaging techniques in dermatology.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/use-of-non-invasive-optical-imaging-techniques-in-dermatology-r347/Weiterlesen

]]>347Tue, 25 Nov 2025 19:50:49 +0000Oral lichen planus in a patient treated with anti-CD20 monoclonal antibodies.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/oral-lichen-planus-in-a-patient-treated-with-anti-cd20-monoclonal-antibodies-r317/No abstract supplied.

Weiterlesen

]]>317Thu, 30 Oct 2025 08:31:24 +0000Auswirkungen auf die Arzneimitteltherapiesicherheit und Adhärenz in der Dermato‐Onkologie: Das AMBORA‐Therapiebegleitungskonzept für orale Antitumortherapeutikahttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/auswirkungen-auf-die-arzneimitteltherapiesicherheit-und-adh%C3%A4renz-in-der-dermato%E2%80%90onkologie-das-ambora%E2%80%90therapiebegleitungskonzept-f%C3%BCr-orale-antitumortherapeutika-r316/No abstract supplied.

Weiterlesen

]]>316Thu, 30 Oct 2025 08:31:24 +0000Oraler Lichen planus bei einer mit monoklonalen Anti‐CD20‐Antikörpern behandelten Patientinhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/oraler-lichen-planus-bei-einer-mit-monoklonalen-anti%E2%80%90cd20%E2%80%90antik%C3%B6rpern-behandelten-patientin-r315/No abstract supplied.

Weiterlesen

]]>315Thu, 30 Oct 2025 08:31:24 +0000Dithranoltherapie bei Psoriasis: eine Pilotstudie zur in vivo konfokalen Laserscanmikroskopiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/dithranoltherapie-bei-psoriasis-eine-pilotstudie-zur-in-vivo-konfokalen-laserscanmikroskopie-r314/No abstract supplied.

Weiterlesen

]]>314Thu, 30 Oct 2025 08:31:24 +0000Bimekizumab plus topical photochemotherapy effective in palmoplantar pustulosis in a patient with hidradenitis suppurativa.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/bimekizumab-plus-topical-photochemotherapy-effective-in%C2%A0palmoplantar-pustulosis-in-a-patient-with%C2%A0hidradenitis-suppurativa-r291/No abstract supplied.

Weiterlesen

]]>291Sun, 19 Oct 2025 14:34:58 +0000Shame-related disorders in patients with atopic dermatitis and psoriasis - An exploratory, cross-sectional interview study on the prevalence and correlates of body dysmorphic disorder and social anxiety disorder.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/shame-related-disorders-in-patients-with-atopic-dermatitis-and-psoriasis-an-exploratory-cross-sectional-interview-study-on-the-prevalence-and-correlates-of-body-dysmorphic-disorder-and-social-anxiety-disorder-r290/Background and objectivesAtopic dermatitis (AD) and psoriasis (Pso) are frequently associated with psychological distress. This study evaluated the prevalence and correlates of shame-related disorders (SRD), namely body dysmorphic disorder (BDD) and social anxiety disorder (SAD), in patients with AD and Pso.

Patients and methods

A monocentric, cross-sectional study was conducted in adult patients from 07/2023 to 03/2024. A trained clinical psychologist assessed subjects for BDD and SAD. Additionally, subjects completed the DLQI. Objective severity of their disease was physician-rated using the EASI or PASI.

Results

One hundred and fifty-one patients were included, n = 55 (36.4%) with AD and n = 96 (63.6%) with Pso. Among all study participants, the point and lifetime prevalence of SRD was 17.2% and 31.8%, respectively. Point and lifetime prevalence for BDD was 10.6% and 26.5%, and for SAD 12.6% and 17.2%. There were no differences in the point or lifetime prevalence of BDD or SAD between patients with AD or Pso. SRD were associated with younger age and female sex. DLQI was significantly reduced in those suffering from SRD.

Conclusions

Our results indicate that SRD are prevalent in AD and Pso and should therefore be further investigated for their use in routine clinical practice.

Weiterlesen

]]>290Sun, 19 Oct 2025 14:34:58 +0000Biologic treatments for psoriasis have different anatomical specificities in residual PASI.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/biologic-treatments-for-psoriasis-have-different-anatomical-specificities-in-residual-pasi-r269/Background and objectivesImproved understanding of the immunopathogenesis of psoriasis has led to the development of effective targeted therapies, but patients who respond to treatment without total skin clearance have residual disease. The aim of this study was to demonstrate the existence of specific residual disease (or residual PASI) anatomical localizations related to different biologic agents.

Methods and patients

This retrospective, observational, multi-center study analyzed clinical data of patients affected by psoriasis who had received biologic treatments for at least 6 months. The data analysis focused on patients with residual PASI.

Results

A total of 228 of 1,000 patients showed residual disease despite achieving PASI 90 at weeks 24-28 of biologic treatment. The anatomical sites most frequently involved in residual disease were the lower limbs (44.3%). We observed differences among the biologic agents in terms of frequency and localization of residual disease. The localization of residual skin lesions to lower limbs was associated with treatment switching/interruption. The drugs with the highest and lowest proportion of patients with residual disease in the lower limbs were, respectively, secukinumab and risankizumab.

Conclusions

Treatment with anti-IL-17 and anti-IL-23 drugs is characterized by the persistence of residual skin lesions with differences in terms of frequency and anatomical localizations.

Weiterlesen

]]>269Tue, 14 Oct 2025 14:32:51 +0000The diagnosis of early-stage mycosis fungoides: Views held by experts and non-experts in cutaneous lymphoma.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/the-diagnosis-of-early-stage-mycosis-fungoides-views-held-by-experts-and-non-experts-in-cutaneous-lymphoma-r258/Background and objectivesMycosis fungoides (MF) accounts for the majority of cutaneous lymphomas (CL). There is a documented delay in the diagnosis of early-stage MF. However, its timely diagnosis is paramount to avoid potentially harmful therapies and undue patient distress. The aim of this study was to examine and compare the views held by both specialists and non-specialists in CL regarding the diagnosis of early-stage MF, to identify clinical needs.

Methods

Two distinct questionnaires were distributed to physicians, who either have a potential or no special interest in CL (non-specialists), or who have a special interest in CL (specialists) and who were identified by participation in the PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study.

Results

Survey results were received from 382 participants, 86 specialists, and 296 non-specialists. In total, 82% of respondents held the view that the diagnosis of early-stage MF is delayed. The frequent misclassification of MF as a benign inflammatory dermatosis was identified as the most important contributing factor.

Conclusions

Non-specialists assume that a delayed diagnosis impairs therapeutic efficacy and prognosis in MF, while specialists primarily suspect negative effects on patients' health-related quality of life. Our study reveals an unmet need to promote education and increase awareness among dermatologists regarding the impact of early-stage MF on patient management.

Weiterlesen

]]>258Fri, 10 Oct 2025 06:15:28 +0000Diagnose der Mycosis fungoides im Frühstadium: Ansichten von Experten und Nicht‐Experten für kutane Lymphomehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/diagnose-der-mycosis-fungoides-im-fr%C3%BChstadium-ansichten-von-experten-und-nicht%E2%80%90experten-f%C3%BCr-kutane-lymphome-r257/No abstract supplied.

Weiterlesen

]]>257Fri, 10 Oct 2025 06:15:28 +0000Unerwünschte Wirkungen von Januskinase‐Inhibitoren mit Relevanz für den dermatologischen Klinik‐ und Praxisalltaghttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/unerw%C3%BCnschte-wirkungen-von-januskinase%E2%80%90inhibitoren-mit-relevanz-f%C3%BCr-den-dermatologischen-klinik%E2%80%90-und-praxisalltag-r256/No abstract supplied.

Weiterlesen

]]>256Fri, 10 Oct 2025 06:15:28 +0000Adverse effects of Janus kinase inhibitors with relevance for daily practice in dermatology.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/adverse-effects-of-janus-kinase-inhibitors-with-relevance-for-daily-practice-in-dermatology-r255/Weiterlesen

]]>255Fri, 10 Oct 2025 06:15:28 +0000Successful treatment of palmoplantar pustulosis with topical ruxolitinib.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/successful-treatment-of-palmoplantar-pustulosis-with-topical-ruxolitinib-r244/No abstract supplied.

Weiterlesen

]]>244Thu, 04 Sep 2025 18:54:25 +0000Impfen in der Dermatologie 2025: Update mit Berücksichtigung aktueller Empfehlungen der Ständigen Impfkommissionhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/impfen-in-der-dermatologie-2025-update-mit-ber%C3%BCcksichtigung-aktueller-empfehlungen-der-st%C3%A4ndigen-impfkommission-r200/No abstract supplied.

Weiterlesen

]]>200Sat, 23 Aug 2025 07:41:29 +0000Vitiligohttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/vitiligo-r199/No abstract supplied.

Weiterlesen

]]>199Sat, 23 Aug 2025 07:41:29 +0000Vitiligohttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/vitiligo-r198/No abstract supplied.

Weiterlesen

]]>198Sat, 23 Aug 2025 07:41:29 +0000Pyoderma gangrenosum and spider bites: a case series.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/pyoderma-gangrenosum-and-spider-bites-a-case-series-r197/No abstract supplied.

Weiterlesen

]]>197Sat, 23 Aug 2025 07:41:29 +0000A phase IIb single-center study to assess the efficacy of apremilast for the treatment of nummular eczema.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/a-phase-iib-single-center-study-to-assess-the-efficacy-of-apremilast-for-the-treatment-of-nummular-eczema-r196/BackgroundThe pathogenesis of nummular eczema (NE) remains unclear, and no targeted therapy has been approved. Apremilast is a small molecule inhibitor targeting phosphodiesterase-4.

Patients and methods

A phase IIb randomized, double-blind, placebo-controlled study evaluating the effects of apremilast or placebo in patients with NE. Patients received apremilast (30 mg BID) or placebo until week 16 followed by an open label phase in which all patients were treated with apremilast until week 32. The primary endpoint was the number of patients achieving an improvement in Physician's Global Assessment (PGA) by two or more points or an absolute PGA of 0 or 1 at week 16. Secondary endpoints included changes in skin physiology, life quality, or dermato-pathology.

Results

33 patients were enrolled, of whom 31 were randomized to apremilast (n  =  15) or placebo (n  =  16). 1/15 (6.7%) patients in the apremilast group and 4/16 (25.0%) in the placebo group reached the primary endpoint (p  =  0.369). There was no difference between placebo and apremilast with regard to all secondary endpoints at week 16 and week 32. The safety profile was in accordance with the known safety profile of apremilast.

Conclusion

Phosphodiesterase-4 inhibition by apremilast showed no beneficial effects for the treatment of NE.

Weiterlesen

]]>196Sat, 23 Aug 2025 07:41:29 +0000Pyoderma gangrenosum und Spinnenbisse: eine Fallseriehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/pyoderma-gangrenosum-und-spinnenbisse-eine-fallserie-r195/No abstract supplied.

Weiterlesen

]]>195Sat, 23 Aug 2025 07:41:29 +0000